dndi update: global partnership addressing needs of most neglected from research to access
DESCRIPTION
DNDi Update: Global Partnership Addressing Needs of Most Neglected From Research to Access. Dr Monique Wasunna KEMRI/Head of DNDi Africa AEMI meeting Cape Town December 13-15 2010. DNDi’s HISTORY. 1999 - PowerPoint PPT PresentationTRANSCRIPT
DNDi Update: Global Partnership Addressing Needs
of Most NeglectedFrom Research to Access
Dr Monique WasunnaKEMRI/Head of DNDi Africa
AEMI meeting Cape Town
December 13-15 2010
DNDi’s HISTORY• 1999
– First meeting in Paris to describe the lack of R&D for neglected diseases (the day MSF received the Nobel Peace Prize)
– MSF commits the Nobel Peace Prize money to the Drugs for Neglected Diseases Working Group
– Jama’s article (01/27/99), “Access to essential drugs in poor countries - A Lost Battle?”, B. Pécoul and all.
• 2001 – DND WG recommends the creation of DNDi
• July 2003– Creation of DNDi (7 founding members
Brazil
India
Kenya
Malaysia
USA
DRC
Japan
Geneva Coordination Team + consultants
7 Founding Partners
• Indian Council for Medical Research (ICMR)
• Kenya Medical Research Institute (KEMRI)
• Malaysian MOH• Oswaldo Cruz Foundation
Brazil• Medecins Sans Frontieres
(MSF)• Institut Pasteur France• WHO/TDR (permanent
observer)
7 worldwide offices
• Non-profit drug research & development (R&D) organization founded in 2003
• Addressing the needs of the most neglected patients
• Harnessing resources from public institutions, private industry and philanthropic entities
A New Model for Drug Development: DNDi created in 2003
VISION • To improve the quality of life and health of
people suffering from neglected diseases- by using an alternative model to develop drugs for these diseases- ensuring equitable access to new and field relevant health tools- not for profit model driven by public sector and partners- build public responsibility and leadership in addressing the needs of these patients
MISSION• To develop new drugs or new
formulations of existing drugs for patients suffering from the most neglected diseases
DNDi’s Main Objectives• Deliver 6 to 8 new treatments
by 2014 for sleeping sickness, Chagas disease, leishmaniasis and malaria
• Establish a robust pipeline for future needs
• Use and strengthen existing capacity in disease-endemic countries
• Raise awareness and advocate for increased public responsibility
7-Year Results• 2 new malaria treatments• 1 new sleeping sickness combination• 1 new visceral leishmaniasis combination
for Africa• Largest pipeline ever for the kinetoplastid
diseases• Clinical research platforms in Africa• On track to deliver new treatments per
business plan
CURRENT STATUS• 4 treatments delivered
- 2007 fixed dose Artesunate/Amodaiaquine (ASAQ) Sanofi Aventis(France)- 2008 ASMQ Farmanguinhos and Cipla- 2009 Nifurtimox/Eflornithine co adminstration (NECT) National Control programmes, MSF/Epicentre, Bayer, Sanofi Aventis, WHO
-2010 SSG+Paromomycin combination RX for VL in EA now recommended by WHO and MOH Sudan has recommended as first line Rx for VL
Challenges to build innovation and research capacities in Africa
• Public leadership to define R&D priorities
• Significant investment with sustainable funding
• Ensure better access to knowledge and promote innovative IP management policies
• Enable more adapted regulatory environment
• Transfer technology and strengthen research capacities in developing countries
By working together in a creative way, south south can bring
innovation to neglected patients!
Thank you
SUDAN: 2 sites (Kassab, Dooka)Univ. of Khartoum Federal Ministry of Health
ETHIOPIA: 2 sites(Gondar, Arba Minch)Addis Ababa Univ.Gondar Univ.Ministry of Health
KENYA: 2 sites (Nairobi, Kimalel)KEMRIMinistry of Health
UGANDA: 1 site (Amudat)• Makerere Univ.• Ministry of Health
MSFI+ solutionsLSH&TMAMC/ SU/ KIT (ASK)IOWH - IndiaIndustry partners
VL
Objectives:
Partners:
LEAP Objectives
• Facilitate clinical testing and registration of new treatments for VL in the region (Ethiopia, Kenya, Sudan and Uganda)
• Evaluate, validate and register improved options that address regional needs for VL
• Provide capacity strengthening for drug evaluation and clinical studies in the region
Infrastructure upgrades
Previous VL Treatment ward Gondar
Current VL Treatment centre and Physiotherapy Dept,
Gondar
LEAP Activities
Renovation and re-equipping of clinical laboratories to high standards
Capacity strengthening
Regional pool of clinical trial expertise
• Serve as forum for members to share their clinical & research experience• Support the review and roll out of VL National Guidelines for member countries
Sharing of experiences between
South-South LEAP scientits
HAT Strengthening Clinical Trial Capacity
PlatformObjectivesTo strengthen clinical trial capacity for sleeping sicknessTo overcome health system challenges for clinical researchTo share information on HAT research progressTo improve HAT clinical trial methodologies
Partners:• National HAT control programs of
most affected endemic countries• DNDi, STI• Research institutes like ITMA, INRB,
CDC, KARI-TRC• NGOs like MSF, Epicentre• FIND, WHO• Regional networks - eg. EANETT,
PABIN, AMANET